Pollak, Thomas A. http://orcid.org/0000-0002-6171-0810
Kempton, Matthew J.
Iyegbe, Conrad
Vincent, Angela http://orcid.org/0000-0003-2395-8695
Irani, Sarosh R.
Coutinho, Ester
Menassa, David A.
Jacobson, Leslie
de Haan, Lieuwe
Ruhrmann, Stephan
Sachs, Gabriele
Riecher-Rössler, Anita
Krebs, Marie-Odile
Amminger, Paul
Glenthøj, Birte
Barrantes-Vidal, Neus
van Os, Jim
Rutten, Bart P. F. http://orcid.org/0000-0002-9834-6346
Bressan, Rodrigo A.
van der Gaag, Mark http://orcid.org/0000-0002-3525-6415
Yolken, Robert
Hotopf, Matthew
Valmaggia, Lucia
Stone, James http://orcid.org/0000-0003-3051-0135
David, Anthony S.
Calem, Maria
Tognin, Stefania
Modinos, Gemma
de Haan, Lieuwe
van der Gaag, Mark
Velthorst, Eva
Kraan, Tamar C.
van Dam, Daniella S.
Burger, Nadine
Nelson, Barnaby
McGorry, Patrick
Pantelis, Christos
Politis, Athena
Goodall, Joanne
Borgwardt, Stefan
Ittig, Sarah
Studerus, Erich
Smieskova, Renata
Gadelha, Ary
Brietzke, Elisa
Asevedo, Graccielle
Asevedo, Elson
Zugman, Andre
Rosa, Araceli
Racioppi, Anna
Monsonet, Manel
Hinojosa-Marqués, Lídia
Kwapil, Thomas R.
Kazes, Mathilde
Daban, Claire
Bourgin, Julie
Gay, Olivier
Mam-Lam-Fook, Célia
Nordholm, Dorte
Randers, Lasse
Krakauer, Kristine
Glenthøj, Louise
Nordentoft, Merete
Gebhard, Dominika
Arnhold, Julia
Klosterkötter, Joachim
Lasser, Iris
Winklbaur, Bernadette
Delespaul, Philippe A.
van Os, Jim
McGuire, Philip
,
Funding for this research was provided by:
RCUK | Medical Research Council (MR/J008915/1)
Wellcome Trust (104079/Z/14/Z)
Agence Nationale de la Recherche (08-MNP-007)
Generalitat de Catalunya (2017SGR1612)
Article History
Received: 21 April 2019
Revised: 28 July 2020
Accepted: 21 September 2020
First Online: 19 October 2020
Compliance with ethical standards
:
: Dr. Pollak was supported by a clinical research training fellowship grant from the Wellcome Trust (no 105758/Z/14/Z). The European Network of National Schizophrenia Networks Studying Gene- Environment Interactions (EU-GEI) Project is funded by grant agreement HEALTH-F2–2010–241909 (Project EU-GEI) from the European Community’s Seventh Framework Programme. Additional support was provided by a Medical Research Council Fellowship to M Kempton (grant MR/J008915/1). Dr. Irani is supported by a Wellcome Trust Intermediate Fellowship (104079/Z/14/Z), the British Medical Association Research Grants: Vera Down (2013) and Margaret Temple (2017). Dr. Nelson was supported by a NHMRC Senior Research Fellowship. Dr. Glenthøj is the leader of a Lundbeck Foundation Centre of Excellence for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS), which is partially financed by an independent grant from the Lundbeck Foundation based on international review and partially financed by the Mental Health Services in the Capital Region of Denmark, the University of Copenhagen, and other foundations. Her group has also received a research grant from Lundbeck A/S for another independent investigator-initiated study. All grants are the property of the Mental Health Services in the Capital Region of Denmark and administrated by them. She has no other conflicts to disclose. Dr. De Haan has no conflicts to disclose. Dr. Ruhrmann is a project consultant of Boehringer Ingelheim. Bart PF Rutten is funded by a VIDI award number 91718336 from the Netherlands Scientific Organisation. Barnaby Nelson was supported by an NHMRC Senior Research Fellowship (1137687). ASD is supported by the NIHR University College London Hospital (UCLH) Biomedical Research Centre. Dr. Barrantes-Vidal was supported by the Ministerio de Ciencia, Innovación e Universidades (PSI2017-87512-C2-1-R), Generalitat de Catalunya (2017SGR1612 and ICREA Academia Award). Dr Bressan has received research grants from Janssen and the governmental funding research agencies: CAPES, CNPq and FAPESP (2016/022465 and 2011/50740-5) and has participated in speaker bureaus for Janssen and Sanofi-Aventis, all outside the submitted work. The authors acknowledge financial support from the National Institute for Health Research (NIHR) Biomedical Research Centres at the South London and Maudsley NHS Foundation Trust, University College London Hospital and the John Radcliffe Hospital NHS Foundation Trust, Oxford. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. Additional support was provided by the Maudsley Charity (Grant Ref. 980) and Guy’s and St. Thomas’s Charity (Grant Ref. STR130505). These funders had no involvement in study design, data collection, analysis or the decision to submit for publication. The study received financial support by French Government’s Agence Nationale pour la Recherche (ANR, 08-MNP-007) and by the French Health Ministry’s Programme Hospitalier de Recherche Clinique (PHRC, AOM-07-118, ‘Influence of cannabis psychopathological outcome in At risk mental state’ (ICAAR study)). The Sainte-Anne hospital center promoted the study. Additional financial support was obtained from the Institut National de la Santé et de la Recherche Médicale (INSERM, recurrent funding and fellowships) and by Fondation Pierre Deniker. AV and SRI are coapplicants and receive royalties on patent application WO/2010/046716 (U.K. patent no., PCT/GB2009/051441) entitled ‘Neurological Autoimmune Disorders’. The patent has been licensed to Euroimmun AG for the development of assays for LGI1 and other VGKC-complex antibodies. MOK participated on boards (Roche, Janssen) and received financial support from Janssen, Otsuka Lundbeck alliance, EIsai for conference or dissemination initiatives.